CTS-2190

N/A

Report date: 2024/03/28 15:55:23
NMEFirst In Class

Base Information

Drug NameCTS-2190
Drug Alias NameCTS-2190
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein arginine N-methyltransferase 1 inhibitors
TargetsProtein arginine N-methyltransferase 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCytosinLab Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCytosinLab Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A